Dengue shock syndrome: Decoding the pathophysiology;Le syndrome de choc de dengue: Vers un décryptage de la physiopathologie

Medecine Tropicale

Volumn 70, Issue 3, 2010, Pages 288-301

  Devignot, S ^a   Tolou, H ^a   Paris, C P ^a  

^a SERVICE DE SANTÉ DES ARMÉES   (France)

Author keywords

Dengue; Pathophysiology; Shock syndrome

Indexed keywords

ARTICLE; DENGUE; HUMAN; MEDICINE; PATHOPHYSIOLOGY; SCREENING TEST; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; BLOOD; DENGUE VIRUS; DEVELOPING COUNTRY; EVIDENCE BASED MEDICINE; HEALTH SURVEY; HOSPITALIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; REVIEW; RISK FACTOR; VASCULAR ENDOTHELIUM;

BIOLOGICAL MARKER; CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; RANTES; TUMOR NECROSIS FACTOR ALPHA;

BIOLOGICAL MARKERS; CHEMOKINE CCL5; CYTOKINES; DENGUE HEMORRHAGIC FEVER; DENGUE VIRUS; DEVELOPING COUNTRIES; ENDOTHELIUM, VASCULAR; EVIDENCE-BASED MEDICINE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; POPULATION SURVEILLANCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957005961     PISSN: 0025682X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (163)

1. Gublcr DJ, Clark GG. Dengue/dengue hemorrhagic fever: the emergence of a global health problem. Emerg Infect Dis 1995;1:55-7.
2. World Health Organization. Dengue guidelines for diagnosis, treatment, prevention and control: new edition. World Health Organization ed, Geneva, 2009.
3. Halstead SB, Papaevangelou G. Transmission of dengue 1 and 2 viruses in Greece in 1928. Am J Trop Med Hyg 1980;29:635-7.
4. Hammon WM, Rudnick A, Sather GE. Viruses associated with epidemic hemorrhagic fevers of the Philippines and Thailand. Science 1960;131:1102-3.
5. Halstead SB, Yamarat C, Scanlon JE. The Thai hemorrhagic fever epidemic of 1962 (A preliminary report). J Med Assoc Thai 1963;6:449-62.
6. Kouri GP, Guzman MG, Bravo JR, Triana C. Dengue haemorrahgic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. Bull World Health Organ 1989;67:375-80.
7. Dengue haemonrhagic fever (DHF). Increase in number of cases in the Americas 1980-1987. Miy Epidemiol Rec 1990;65:13-5.
8. Fang R, Lo E, Lim TW. The 1982 dengue epidemic in Malaysia: epidemiological, serological and virological aspects. Southeast Asian J Trop Med Public Health 1984;15:51-8.
9. King CC, Wu YC, Chao DY, Lin TH, Lin C, Wang HT et al. Major Epidemics of Dengue in Taiwan in 1981-2000: Related to Intensive Virus Activities in Asia. Dengue Bulletin 2000;24:1-10.
10. Christophers SR. Aedes aegypti the yellow fever mosquito: its life history, bionomics, and structure. Cambridge University Press ed, 1960.
11. Ninove L, Parola P, Baronti C, De Lamballerie X, Gautret P, Doudier B, et al. Dengue virus type 3 infection in traveler returning from w est Africa. Emerg Infect Dis 2009;15:1871-2.
12. Dengue fever. Cape Verde. Wkly Epidemiol Rec 2009;84:469.
13. Rudnick A. Studies of the ecology of dengue in Malaysia: a preliminary report. J Med Entomol 1965;2:203-8.
14. Saluzzo JF, Comet M, Adam C, Eyraud M, Digoutte JP. Dengue 2 au Senegal oriental: enquête sérologique dans les populations simiennes et humaines 1974-85. Bull Soc Pathol Exot 1986;79:313-22.
15. Cardosa J, Ooi MH, Tio PH, Perera D, Holmes EC, Bibi K, et al. Dengue virus serotype 2 from a sylvatic lineage isolated from a patient w ith dengue hemorrhagic Fever. PLoS Negl Trop Dis 2009;3:e423.
16. Paupy C, Delatte H, Bagny L, Corbel V, Fontenille D. Aedes albopictus, an arbovirus vector: from the darkness to the light. Microbes Infect 2009;11:1177-85.
17. Moutailler S, Barre H, Vazeille M, Failloux AB. Recently introduced Aedes albopictus in Corsica is competent to Chikungunya virus and in a lesser extent to dengue virus. Trop Med Int Health 2009;14:1105-9.
18. Guzman MG, Kouri G, Morier L, Soler M, Fernandez A. A study of fatal hemorrhagic dengue cases in Cuba, 1981. Bull Pan Am Health Organ 1984;18:213-20.
19. Khun S, Manderson L. Poverty, user fees and ability to pay for health care for children with suspected dengue in rural Cambodia. Int J Equity Health 2008;7:10.
20. Heintze C, Velasco Garrido M, Kroeger A. What do community-based dengue control programmes achieve? A systematic review of published evaluations. Trans R Soc Trop Med Hyg 2007;101:317-25.
21. Vanlerberghe V, Toledo ME, Rodriguez M, Gomez D, Baly A, Benitez JR, et al. Community involvement in dengue vector control: cluster randomised trial. BMJ 2009;338:bl959.
22. World Health Organization. Dengue haemonrhagic fever, diagnosis, treatment, prevention and control. 2nd edition. World Health Organization ed, Geneva, 1997.
23. Suaya JA, Shepard DS, Siqueira JB, Martelli CT, Lum LC, Tan LH, et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg 2009;80:846-55.
24. Gulati S, Maheshwari A. Atypical manifestations of dengue. Trop Med Int Health 2007;12:1087-95.
25. Lum LC, Lam SK, Choy YS, George R, Harun F. Dengue encephalitis: a true entity? Am J Trop Med Hyg 1996;54:256-9.
26. Solomon T, Dung NM, Vaughn DW, Kneen R, Thao LT, Raengsakulrach B, et al. Neurological manifestations of dengue infection. Lancet 2000;355:1053-9.
27. Kalayanarooj S, Nimmannitya S. Clinical presentations of dengue hemorrhagic fever in infants compared to children. J Med Assoc Thai 2003;86:S673-80.
28. Bravo JR, Guzman MG, Kouri GP. Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Trans R Soc Trop Med Hyg 1987;81:816-20.
29. Guzman MG, Kouri G, Soler M, Bravo J, Rodriguez de La Vega A, Vazquez S, et al. Dengue 2 virus enhancement in asthmatic and non asthmatic individual. Mem Inst Oswaldo Cruz 1992;87:559-64.
30. Gonzalez D, Castro OE, Kouri G, Perez J, Martinez E, Vazquez S, et al Classical dengue hemorrhagic fever resulting from two dengue infections spaced 20 years or more apart: Havana, Dengue 3 epidemic, 2001-2002. Int J Infect Dis 2005;9:280-5.
31. Limonta D, Gonzalez D, Capô V, Torres G, Perez AB, Rosario D, et al. Fatal severe dengue and cell death in sickle cell disease during the 2001-2002 Havana dengue epidemic. Int J Infect Dis 2009;13:e77-8.
32. Bandyopadhyay S, Lum LC, Kroeger A. Classifying dengue: a review of the difficulties in using the WHO case classification for dengue haemorrhagic fever. Trop Med Int Health 2006;11:1238-55.
33. Setiati TE, Mairuhu AT, Koraka P, Supriatna M, MacGillavry MR, Brandjes DP, et al. Dengue disease severity in Indonesian children: an evaluation of the World Health Organization classification system. BMC Infect Dis 2007;7:22.
34. Rigau-Pérez JG. Severe dengue: the need for new case definitions. Lancet Infect Dis 2006;6:297-302.
35. GuzmSn MG, Kouri G, Martinez E, Bravo J, Riverôn R, Soler M, et al. Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Bull Pan Am Health Organ 1987;21:70-9.
36. Peters CJ, Zaki SR. Role of the endothelium in viral hemorrhagic fevers. Crit Care Med 2002;30:S268-73.
37. Aleksandrowicz P, Wolf K, Falzarano D, Feldmann H, Seebach J, Schnittler H. Viral haemorrhagic fever and vascular alterations. Hamostaseologie 2008;28:77-84.
38. Wills BA, Nguyen MD, Ha TL, Dong TH, Tran TN, Le TT, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 2005;353:877-89.
39. Smart K, Safitri I. Evidence behind the WHO guidelines: hospital care for children: what treatments are effective for the management of shock in severe dengue? J Trop Pediatr 2009;55:145-8.
40. Kalayanarooj S. Standardized Clinical Management: Evidence of Reduction of Dengue Haemorrhagic Fever Case-Fatality Rate in Thailand. Dengue Bulletin 1999;23:10-17.
41. Chaturvedi UC, Shrivastava R. Dengue haemorrhagic fever: A global challenge. Indian J Med Microbiol 2004;22:5-6.
42. Sahaphong S, Riengrojpitak S, Bhamarapravati N, Chirachariyavej T. Electron microscopic study of the vascular endothelial cell in dengue hemorrhagic fever. Southeast Asian J Trop Med Public Health 1980;11:194-204.
43. Rosen L. The Emperor's New Clothes revisited, or reflections on the pathogenesis of dengue hemorrhagic fever. Am J Trop Med Hyg 1977;26:337-43.
44. Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, Westaway EG, et al. Antigenic relationships between flaviviruses as determined by crossneutralization tests with polyclonal antisera. J Gen Virol 1989;70:37-43.
45. Rico-Hesse R. Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology 1990;174:479-93.
46. Guzman MG, Kouri G, Valdés L, Bravo J, Vazquez S, Halstead SB. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salad Publico 2002;11:223-7.
47. Rico-Hesse R. Microevolution and virulence of dengue viruses. Adv Virus Res 2003;59:315-41.
48. Rico-Hesse R, Harrison LM, Salas RA, Tovar D, Nisalak A, Ramos C, et al. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 1997;230:244-51.
49. Cologna R, Rico-Hesse R. American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J Virol 2003;77:3929-38.
50. Anderson JR, Rico-Hesse R. Aedes aegypti vectorial capacity is determined by the infecting genotype of dengue virus. Am J Trop Med Hyg 2006;75:886-92.
51. Guzman MG, Kouri G. Dengue: an update. Lancet Infect Dis 2002;2:33-42.
52. Cologna R, Armstrong PM, Rico-Hesse R. Selection for virulent dengue viruses occurs in humans and mosquitoes. J Virol 2005;79:853-9.
53. Tolou H, Couissinier-Paris P, Mercier V, Pisano MR, de Lamballerie X, de Micco P, et al. Complete genomic sequence of a dengue type 2 virus from the French West Indies. Biochem Biophys Res Commun 2000;277:89-92.
54. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakom S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000;181:2-9.
55. Murgue B, Roche C, Chungue E, Deparis X. Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia. J Med Virol 2000;60:432-8.
56. Wang WK, Chao DY, Kao CL, Wu HC, Liu YC, Li CM, et al. High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis. Virology 2003;305:330-8.
57. Guilarde AO, Turchi MD, Siqueira JB Jr., Feres VC, Rocha B, Levi JE, et al. Dengue and dengue hemorrhagic fever among adults: clinical outcomes related to viremia, serotypes, and antibody response. J Infect Dis 2008;197:817-24.
58. Library DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, Green S, et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis 2002;186:1165-8.
59. Thayan R, Huat TL, See LL, Tan CP, Khairullah NS, Yusof R, et al. The use of twodimension elecuophoresis to identify serum biomarkers from patients with dengue haemorrhagic fever. Trans RSoc Trop Med Hyg 2009;103:413-9.
60. Mufioz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle M, Garcia-Sastre A. Inhibition of interferon signaling by dengue virus. Proc Nail Acad Sci USA 2003;100:14333-8.
61. Munoz-Jordan JL, Laurent-Rolle M, Ashour J, Martinez-Sobrido L, Ashok M, Lipkin WI, et al. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol 2005;79:8004-13.
62. Nguyen TH, Nguyen TL, Lei IIY, Lin YS, Le BL, Huang KJ, et al. Association between sex, nutritional status, severity of dengue hemorrhagic fever, and immune status in infants with dengue hemorrhagic fever. Am J Trop Med Hyg 2005;72:370-4.
63. Pichainarong N, Mongkalangoon N, Kalayanarooj S, Chaveepojnkamjorn W. Relationship between body size and severity of dengue hemorrhagic fever among children aged 0-14 years. Southeast Asian J Trop Med Public Health 2006;37:283-8.
64. Halstead SB, Streit TG, Lafontant JG, Putvatana R, Russell K, Sun W, et al. Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am J Trop Med Hyg 2001;65:180-3.
65. de la C Sierra B, Garcia G, Pérez AB, Morier L, Alvarez M, Kouri G, et al. Ethnicity and difference in dengue virus-specific memory T cell responses in Cuban individuals. Viral Immunol 2006;19:662-8.
66. de la C Sierra B, Kouri G, Guzmin MG. Race: a risk factor for dengue hemorrhagic fever. Arch Virol 2007;152:533-42.
67. Blanton RE, Silva LK, Morato VG, Parrado AR, Dias JP, Melo PR, et al. Genetic ancestry and income are associated with dengue hemorrhagic fever in a highly admixed population. Eur J Hum Genet 2008;16:762-5.
68. Chaturvedi U, Nagar R, Shrivastava R. Dengue and dengue haemorrhagic fever: implications of host genetics. FEMS Immunol Med Microbiol 2006;47:155-66.
69. Coffey LL, Mertens E, Brehin AC, Fernandez-Garcia MD, Amara A, Després P, et al. Human genetic determinants of dengue virus susceptibility. Microbes Infect 2009;11:143-56.
70. Kalayanarooj S, Gibbons RV, Vaughn D, Green S, Nisalak A, Jarman RG, et al. Blood group AB is associated with increased risk for severe dengue disease in secondary infections. J Infect Dis 2007;195:1014-7.
71. Hammond SN, Balmaseda A, Pérez L, Tellez Y, Saborio SI, Mercado JC, et al. Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. Am J Trop Med Hyg 2005;73:1063-70.
72. Guzman MG, Kouri G, Bravo J, Valdes L, Vazquez S, Halstead SB. Effect of age on outcome of secondary dengue 2 infections. Int J Infect Dis 2002;6:118-24.
73. World Health Organization. Prevention and control of dengue and dengue haemorrhagic fever: comprehensive guidelines: WHO Regional Publication, SEARO; 1999.
74. Kittigul L, Pitakamjanakul P, Sujirarat D, Siripanichgon K. The differences of clinical manifestations and laboratory findings in children and adults with dengue virus infection. J Clin Virol 2007;39:76-81.
75. Gamble J, Bethell D, Day NP, Loc PP, Phu NH, Gartside IB, et al. Age-related changes in microvascular permeability: a significant factor in the susceptibility of children to shock? Clin Sci 2000;98:211-6.
76. Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and vims recovered. Yale J Biol Med 1970;42:311-28.
77. Thein S, Aung MM, Shwe TN, Aye M, Zaw A, Aye K, et al. Risk factors in dengue shock syndrome. Am J Trop Med Hyg 1997;56:566-72.
78. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004;189:990-1000.
79. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988;239:476-81.
80. Deparis X, Maréchal V, Matheus S. Mécanismes physiopathologiques de la dengue: revue critique des hypothèses. Med Trop 2009;69:351-7
81. Kliks SC. Nimmanitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988;38:411-9.
82. Simmons CP, Chau TN, Thuy IT, Tuan NM, Hoang DM, Thien NT, et al Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect DÙ 2007;196:416-24.
83. Halstead SB, O'Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 1977;146:201-17.
84. Gubler DJ, Suharyono W, Tan R, Abidin M, Sie A. Viraemia in patients with naturally acquired dengue infection. Bull World Health Organ 1981;59:623-30.
85. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003;9:921-7.
86. Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Janus J, et al. Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J Clin Invest 1991;88:1473-80.
87. Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakom S, Nisalak A, et al. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis 1999;179:755-62.
88. Mangada MM, Endy TP, Nisalak A, Chunsuttiwat S, Vaughn DW, Library DU, et al. Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren. J Infect Dis 2002;185:1697-703.
89. Mangada MM, Rothman AL. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol 2005;175:2676-83.
90. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, Potts JA, et al. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med 2009;6:e1000171
91. Laoprasopwattana K, Libraty DH, Endy TP, Nisalak A, Chunsuttiwat S, Vaughn DW, et al. Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis 2005;192:510-9.
92. Ong A, Sandar M, Chen MI, Sin LY. Fatal dengue hemorrhagic fever in adults during a dengue epidemic in Singapore. Int J Infect Dis 2007;11:263-7.
93. Harris E, Videa E, Perez L, Sandoval E, Téllez Y, Pérez ML, et al. Clinical, epidemiologic, and virologie features of dengue in the 1998 epidemic in Nicaragua. Am J Trop Med Hyg 2000, 63:5-11.
94. Thomas S, Redfem JB, Lidbury BA, Mahalingam S. Antibody-dependent enhancement and vaccine development. Expert Rev Vaccines 2006;5:409-12.
95. Durbin AP, Whitehead SS. Dengue vaccine candidates in development. Curr Top Microbiol Immunol 2010;338:129-43.
96. Chaturvedi UC, Agarwal R, Elbishbishi EA, Mustafa AS. Cytokine cascade in dengue hemorrhagic feven implications for pathogenesis. FEMS Immunol Med Microbiol 2000;28:183-8.
97. Pang T, Cardosa MJ, Guzman MG. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol Cell Biol 2007;85:43-5.
98. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med 2008;26:711-5.
99. Sriskandan S, Altmann DM. The immunology of sepsis. J Pathol 2008;214:211-23.
100. Dewi BE, Takasaki T, Kurane I. In vitro assessment of human endothelial cell permeability: effects of inflammatory cytokines and dengue virus infection. J Virol Methods 2004;121:171-80.
101. Hober D, Poli L, Roblin B, Gestas P, Chungue E, Granic G, et al. Serum levels of tumor necrosis factor-alpha (TNF-alpha), interieukin-6 (TL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med Hyg 1993;48:324-31.
102. Hober D, Delannoy AS, Benyoucef S, De Groote D, Wattré P. High levels of sTNFR p75 and TNF alpha in dengue-infected patients. Microbiol Immunol 1996;40:569-73.
103. Braga EL, Moura P, Pinto LM, Ignacio SR, Oliveira MJ, Cordeiro MT, et al. Detection of circulant tumor necrosis factor-alpha, soluble tumor necrosis factor p75 and interferon-gamma in Brazilian patients with dengue fever and dengue hemorrhagic fever. Mem Inst Osivaldo Cruz 2001;96:229-32.
104. Wang L, Chen RF, Liu JW, Yu HR, Kuo HC, Yang KD. Implications of dynamic changes among tumor necrosis factor-alpha (TNF-alpha), membrane TNF receptor, and soluble TNF receptor levels in regard to the severity of dengue infection. Am J Trop Med Hyg 2007;77:297-302.
105. Levy A, Valero N, Espina LM, Annez G, Arias J, Mosquera J. Increment of interleukin 6, tumour necrosis factor alpha, nitric oxide, C-reactive protein and apoptosis in dengue. Trans R Soc Trop Med Hyg 2009;104:16-23.
106. Library DH, Endy TP, Houng HS, Green S, Kalayanarooj S, Suntayakom S, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002;185:1213-21.
107. Bethell DB, Flobbe K, Cao XT, Day NP, Pham TP, Buurman WA, et al. Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever. J Infect Dis 1998;177:778-82.
108. Laur F, Murgue B, Deparis X, Roche C, Cassar O, Chungue E. Plasma levels of tumour necrosis factor alpha and transforming growth factor beta-1 in children with dengue 2 virus infection in French Polynesia. Trans R Soc Trop Med Hyg 1998;92:654-6.
109. Chen LC, Lei HY, Liu CC, Shiesh SC, Chen SH, Liu HS, et al. Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients. Am J Trop Med Hyg 2006;74:142-7.
110. Bozza FA, Cruz OG, Zagne SM, Azeredo EL, Nogueira RM, Assis EF, et al. Multiplex cytokine profile from dengue patients: MIP-1 beta and IFN-gamma as predictive factors for severity. BMC Infect Dis 2008;8:86.
111. Priyadarshini D, Gadia RR, Tripathy A, Gurukumar KR, Bhagat A, Patwardhan S, et al. Clinical findings and pro-inflammatory cytokines in dengue patients in Western India: a facility-based study. PLoS One 2010;5:e8709.
112. Juffrie M, Meer GM, Hack CE, Haasnoot K, Sutaryo, Veerman AJ, et al. Inflammatory mediators in dengue virus infection in children: interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2. Am J Trop Med Hyg 2001;65:70-5.
113. Raghupathy R, Chaturvedi UC, Al-Sayer H, Elbishbishi EA, Agarwal R, Nagar R, et al. Elevated levels of IL-8 in dengue hemorrhagic fever. J Med Virol 1998;56:280-5.
114. Mustafa AS, Elbishbishi EA, Agarwal R, Chaturvedi UC. Elevated levels of interleukin-13 and IL-18 in patients with dengue hemorrhagic fever. FEMS Immunol Med Microbiol 2001;30:229-33.
115. Lee YR, Liu MT, Lei HY, Liu CC, Wu JM, Tung YC, et al. MCP-1, a highly expressed chemokine in dengue haemorrhagic fever/dengue shock syndrome patients, may cause permeability change, possibly through reduced tight junctions of vascular endothelium cells. J Gen Virol 2006;87:3623-30.
116. Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakom S, Nisalak A, et al. Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity. J Med Virol 1999;59:329-34.
117. Perez AB, Garcia G, Sierra B, Alvarez M, Vazquez S, Cabrera MV, et al. IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba. J Med Virol 2004;73:230-4.
118. Chen RF, Liu JW, Yeh WT, Wang L, Chang JC, Yu HR, et al. Altered T helper 1 reaction but not increase of virus load in patients with dengue hemorrhagic fever. FEMS Immunol Med Microbiol 2005;44:43-50.
119. Pacsa AS, Agarwal R, Elbishbishi EA, Chaturvedi UC, Nagar R, Mustafa AS. Role ofinterieukin-12in patients with dengue hemorrhagic fever. FEMS Immunol Med Microbiol 2000;28:151-5.
120. Azeredo EL, De Oliveira-Pinto LM, Zagne SM, Cerqueira DI, Nogueira RM, Kubelka CF. NK cells, displaying early activation, cytotoxicity and adhesion molecules, are associated with mild dengue disease. Clin Exp Immunol 2006;143:345-56.
121. Azizan A, Fitzpatrick K, Signorovitz A, Tanner R, Hernandez H, Stark L, et al. Profile of time-dependent VEGF upregulation in human pulmonary endothelial cells, HPMEC-ST1.6R infected with DENV-1, -2, -3, and -4 viruses. Virol J 2009;6:49.
122. Tseng CS, Lo HW, Teng HC, Lo WC, Ker CG. Elevated levels of plasma VEGF in patients with dengue hemorrhagic fever. FEMS Immunol Med Microbiol 2005;43:99-102.
123. Srikiatkhachom A, Ajariyakhajorn C, Endy TP, Kalayanarooj S, Libraty DH, Green S, et al. Virus-induced decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic Fever. J Virol 2007;81:1592-600.
124. Sathupan P, Khongphattanayothin A, Srisai J, Srikaew K, Poovorawan Y. The role of vascular endothelial growth factor leading to vascular leakage in children with dengue virus infection. Ann Trop Paediatr 2007;27:179-84.
125. Seet RC, Chow AW, Quek AM, Chan YH, Lim EC. Relationship between circulating vascular endothelial growth factor and its soluble receptors in adults with dengue virus infection: a case-control study. Int J Infect Dis 2009;13:e248-53.
126. Khongphatthanayothin A, Phumaphuti P, Thongchaiprasit K, Poovorawan Y. Serum levels of sICAM-1 and sE-selectin in patients with dengue virus infection. Jpn J Infect Dis 2006;59:186-8.
127. Murgue B, Cassar O, Deparis X. Plasma concentrations of sVCAM-1 and severity of dengue infections. J Med Virol 2001;65:97-104.
128. Koraka P, Murgue B, Deparis X, Van Gorp EC, Setiati TE, Osterhaus AD, et al. Elevation of soluble VCAM-1 plasma levels in children with acute dengue virus infection of varying severity. J Med Virol 2004;72:445-50.
129. Bokisch VA, Top FH Jr, Russell PK, Dixon FJ, Muller-Eberhard HJ. The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med 1973;289:996-1000.
130. Avirutnan P, Punyadee N, Noisakran S, Komoltri C, Thiemmeca S, Auethavomanan K, et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 2006;193:1078-88.
131. Nascimento EJ, Silva AM, Cordeiro MT, Brito CA, Gil LH, Braga-Neto U, et al. Alternative complement pathway deregulation is correlated with dengue severity. PioS One 2009;4:e6782.
132. Falconar AK. The dengue virus nonstructural-1 protein (NSI) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Arch Virol 1997;142:897-916.
133. Mitrakul C, Poshyachinda M, Futrakul P, Sangkawibha N, Ahandrik S. Hemostatic and platelet kinetic studies in dengue hemorrhagic fever. Am J Trop Med Hyg 1977;26:975-84.
134. Lin CF, Lei HY. Liu CC, Liu HS, Yeh TM, Wang ST, et al. Generation of IgM anti-platelet autoantibody in dengue patients. J Med Virol 2001;63:143-9.
135. Lin CF, Chiu SC, Hsiao YL, Wan SW, Lei H Y, Shiau AL, et al. Expression of cytokine, chemokine, and adhesion molecules during endothelial cell activation induced by antibodies against dengue virus nonstructural protein 1. J Immunol 2005;174:395-403.
136. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007;100:158-73.
137. Aird WC. Endothelium in health and disease. Pharmacol Rep 2008;60:139-43.
138. Bonner SM, O'Sullivan MA. Endothelial cell monolayers as a model system to investigate dengue shock syndrome. J Virol Methods 1998;71:159-67.
139. Jessie K, Fong MY, Devi S, Lam SK, Wong KT. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis 2004;189:1411-8.
140. Azizan A, Sweat J, Espino C, Gemmer J, Stark L, Kazanis D. Differential proinflammatory and angiogenesis-specific cytokine production in human pulmonary endothelial cells, HPMEC-ST1.6R infected with dengue-2 and dengue-3 virus. J Virol Methods 2006;138:211-7.
141. Peyrefitte CN, Pastorino B, Grau GE, Lou J, Tolou H, Couissinier-Paris P. Dengue virus infection of human microvascular endothelial cells from different vascular beds promotes both common and specific functional changes. J Med Virol 2006;78:229-42.
142. Talavera D, Castillo AM, Dominguez MC, Gutierrez AE, Meza I. IL8 release, tight junction and cytoskeleton dynamic reorganization conducive to permeability increase are induced by dengue virus infection of microvascular endothelial monolayers. J Gen Virol 2004;85:1801-13.
143. Avirutnan P, Malasit P, Seliger B, Bhakdi S, Husmann M. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J Immunol 1998;161:6338-46.
144. Huang YH, Lei HY, Liu HS, Lin YS, Liu CC, Yeh TM. Dengue virus infects human endothelial cells and induces 1L-6 and IL-8 production. Am J Trop Med Hyg 2000;63:71-5.
145. Gavrilovskaya IN, Gorbunova EE, Mackow NA, Mackow ER. Hantaviruses direct endothelial cell permeability by sensitizing cells to the vascular permeability factor VEGF, while angiopoietin 1 and sphingosine 1-phosphate inhibit hantavirusdirected permeability. J Virol 2008;82:5797-806.
146. Dewi BE, Takasaki T, Kurane I. Peripheral blood mononuclear cells increase the permeability of dengue virus-infected endothelial cells in association with downregulation of vascular endothelial cadherin. J Gen Virol 2008;89:642-52.
147. Limonta D, Capé V. Torres G, Pérez AB, Guzmdn MG. Apoptosis in tissues from fatal dengue shock syndrome. J Clin Virol 2007;40:50-4.
148. Kanlaya R, Pattanakitsakul SN, Sinchaikul S, Chen ST, Thongboonkerd V. Alterations in actin cytoskeletal assembly and junctional protein complexes in human endothelial cells induced by dengue virus infection and mimicry of leukocyte transendothelial migration. J Proteome Res 2009;8:2551-62.
149. Luplertlop N, Misse D, Bray D, Deleuze V, Gonzalez JP, Leardkamolkam V, et al. Dengue-virus-infected dendritic cells trigger vascular leakage through metalloproteinase overproduction. EMBO Rep 2006;7:1176-81.
150. Lockhart DJ, Winzeler EA. Genomics, gene expression and DNA arrays. Nature 2000;405:827-36.
151. Cobb JP, Mindrinos MN, Miller-Graziano C, Calvano SE, Baker H V, Xiao W, et al. Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci USA 2005;102:4801-6.
152. Tian L, Greenberg SA, Kong SW, Altschuler J, Kohane IS, Park PJ. Discovering statistically significant pathways in expression profiling studies. Proc Natl Acad Sci USA 2005;102:13544-9.
153. Ruiz-Garcia E, Scott V, Machavoine C, Bidart JM, Lacroix L, Delaloge S, et al. Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening. Br J Cancer 2010;102:462-8.
154. Moses AV, Jam's MA, Raggo C, Bell YC, Ruhl R, Luukkonen BG, et al. Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol 2002;76:8383-99.
155. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
156. Segal NH, Paviidis P, Antonescu CR, Maki RG, Noble WS, De Santis D, et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol 2003;163:691-700.
157. Feezor RJ, Cheng A, Paddock HN, Baker H V, Moldawer LL. Functional genomics and gene expression profiling in sepsis: beyond class prediction. Clin Infect Dis 2005;41:S427-35.
158. Tang BM, McLean AS, Dawes IW, Huang SJ, Lin RC. The use of gene-expression profiling to identify candidate genes in human sepsis. Am J Respir Crit Care Med 2001;176:676-84.
159. Ren Y, He QY, Fan J, Jones B, Zhou Y, Xie Y, et al. The use of proteomics in the discovery of serum biomarkers from patients with severe acute respiratory syndrome. Proteomics 2004;4:3477-84.
160. Simmons CP, Popper S, Dolocek C, Chau TN, Griffiths M, Dung NT, et al. Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J Infect Dis 2007;195:1097-107.
161. Long HT, Hibberd ML, Hien IT, Dung NM, Van Ngoc T, Farrar J, et al. Patterns of gene transcript abundance in the blood of children with severe or uncomplicated dengue highlight differences in disease evolution and host response to dengue virus infection. J Infect Dis 2009;199:537-46.
162. Devignot S, Sapet C, Duong V, Bergon A, Rihet P, Ong S, et al. Genome-wide expression profiling deciphers host responses altered during dengue shock syndrome and reveals the role of innate immunity in severe dengue. En révision.
163. Devignot S, Duong V, Sapet C, Rihet P, Bergon A, Tolou H, et al. Recherche de biomarqueurs biologiques associés au syndrome de choc de dengue chez des patients vivant en zone d'endémie. Med Trop 2009;69:366.